An evidence-based review of natalizumab therapy in the management of Crohn’s disease

Figures & data

Table 1 The Montreal classification of Crohn’s disease⁵

Age at diagnosis (A)	A1 below 16 years
	A2 between 17 and 40 years
	A3 above 40 years
Location (L)	L1 ileal
	L2 colonic
	L3 ileocolonic
	L4 isolated upper diseasea
Behavior (B)	B1 non-stricturing non-penetrating
	B2 stricturing
	B3 penetrating
	P perianal disease modifierb

Notes:

a L4 is a modifier that can be added to L1–L3 when concomitant upper disease is present.

b “P” is added to B1–B3 when concomitant perianal disease is present.

Figure 1 Comparison of response and remission rates for three pivotal studies for natalizumab in moderate to severely active Crohn’s disease (P = 0.05 and P = 0.12 in ENACT-1, P < 0.001 and P = 0.002 in ENCORE and P < 0.001 and P = 0.003 in ENACT-2 for response and remission respectively).

Table 2 “TOUCH” program questionnaire

Over the past month, have you had any new or worsening medical problems (such as a new or sudden change in your thinking, eyesight, balance, strength, or other problems) that have persisted over several days? Do you have a medical condition that can weaken your immune system, such as HIV infection or AIDS, leukemia, or lymphoma, or an organ transplant, that may suggest that your body is not able to fight infections well? In the past month, have you taken medications to treat cancer or MS or any other medicines that weaken your immune system? In the past month, other than for the treatment of a recent relapse, have you taken any of the following medicines: Solu Medrol, methyl prednisone, Decadron, dexamethasone, Depo-Medrol, prednisone or other steroid medicines?

SastangiJSilverbergMSVermeireSColombelJFThe Montreal Classification of inflammatory bowel disease:controversies, consensus and implicationsGut20065574975316698746

 PubMed Web of Science ®Google Scholar